BioInvent has no strategy regrets despite 23% job cuts
This article was originally published in Scrip
In the wake of the recent decision with its partner ThromboGenics to halt further development of TB-402, a long acting coagulant, following disappointing head-to-head results with Xarelto rivaroxaban against venous thromboembolism (VTE) (www.scripintelligence, 5 June, 2012), BioInvent International has decided to refocus its resources which includes a headcount reduction from 89 to 68 employees.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.